MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ
30.05
-1.54
-4.88%
Closed 18:47 05/13 EDT
OPEN
31.69
PREV CLOSE
31.59
HIGH
32.02
LOW
29.99
VOLUME
2.67M
TURNOVER
--
52 WEEK HIGH
121.06
52 WEEK LOW
27.66
MARKET CAP
3.88B
P/E (TTM)
-7.5461
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on Top Healthcare Stocks: Bio-Techne (TECH), Mirum Pharmaceuticals (MIRM)
TipRanks · 1d ago
Weekly Report: what happened at PCVX last week (0505-0509)?
Weekly Report · 1d ago
Invesco Small Cap Growth Fund Q1 2025 Commentary
Seeking Alpha · 2d ago
Vaxcyte’s Long-Term Potential Overshadows Market Challenges: A Buy Recommendation
TipRanks · 5d ago
Vaxcyte GAAP EPS of -$1.04 beats by $0.27
Seeking Alpha · 5d ago
Optimistic Outlook for Vaxcyte’s Vaccines Drives Buy Rating
TipRanks · 6d ago
Vaxcyte Q1 EPS $(1.04) Beats $(1.11) Estimate
Benzinga · 6d ago
BRIEF-Vaxcyte Q1 Cash & Investments USD 2,950.762 Million
Reuters · 6d ago
More
About PCVX
More
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Recently
Symbol
Price
%Change

Webull offers Vaxcyte Inc stock information, including NASDAQ: PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.